- Report
- July 2023
- 96 Pages
Global
From €3500EUR$3,902USD£3,110GBP
- Report
- July 2021
- 109 Pages
Global
From €3200EUR$3,568USD£2,843GBP
- Report
- July 2023
- 94 Pages
Global
From €3500EUR$3,902USD£3,110GBP
- Report
- October 2023
- 146 Pages
Global
From €3389EUR$3,528USD£2,910GBP
€3987EUR$4,150USD£3,423GBP
- Report
- March 2024
- 132 Pages
Global
From €913EUR$950USD£784GBP
- Report
- November 2021
- 1112 Pages
Global
From €5765EUR$6,000USD£4,949GBP
In Situ Hybridization (ISH) is a molecular diagnostic technique used to detect and localize specific nucleic acid sequences within cells and tissues. It is used to detect gene expression, chromosomal abnormalities, and gene mutations. ISH is a powerful tool for diagnosing diseases such as cancer, genetic disorders, and infectious diseases.
ISH involves the use of labeled probes, which are complementary to the target nucleic acid sequence. The probes are hybridized to the target sequence, and the labeled probes are detected using a variety of techniques, such as fluorescence microscopy, immunohistochemistry, and in situ PCR.
ISH is used in a variety of clinical applications, including the diagnosis of cancer, genetic disorders, and infectious diseases. It is also used in research to study gene expression, chromosomal abnormalities, and gene mutations.
Companies in the In Situ Hybridization market include Agilent Technologies, Bio-Rad Laboratories, Merck KGaA, PerkinElmer, and Thermo Fisher Scientific. Show Less Read more